Literature DB >> 12567156

Topiramate for the treatment of kleptomania: a case series and review of the literature.

Pinhas N Dannon1.   

Abstract

Kleptomania--the inability to resist the impulse to steal objects, not for personal use or monetary gain--is currently classified in psychiatric nomenclature as an impulse control disorder. There is no standard pharmacologic therapy for this disorder. If kleptomania was considered a form of obsessive-compulsive disorder, treatments used for this spectrum, including serotonin reuptake inhibitors (SSRI), other antidepressants, opioid receptor antagonist medications, and mood stabilizers, could be logically tested. Topiramate is currently used for the treatment of patients with affective and compulsive eating disorders. This report documents three kleptomanic patients who responded well to topiramate given either alone or in combination with SSRIs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12567156     DOI: 10.1097/00002826-200301000-00001

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

1.  Overview of Kleptomania and Phenomenological Description of 40 Patients.

Authors:  Elias Aboujaoude; Nona Gamel; Lorrin M Koran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 2.  Pathological gambling: an update on neuropathophysiology and pharmacotherapy.

Authors:  Iulian Iancu; Katherine Lowengrub; Yael Dembinsky; Moshe Kotler; Pinhas N Dannon
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Kleptomania and potential exacerbating factors: a review and case report.

Authors:  Farid Ramzi Talih
Journal:  Innov Clin Neurosci       Date:  2011-10

4.  Pathological stealing in dementia: poor response to SSRI medications.

Authors:  Mario F Mendez
Journal:  J Clin Psychiatry       Date:  2011-03       Impact factor: 4.384

Review 5.  Compulsive disorders.

Authors:  John M Kuzma; Donald W Black
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

Review 6.  Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.

Authors:  Angelo Antonini; Roberto Cilia
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial.

Authors:  Ahmad Ghanizadeh; Mohammad Reza Mohammadi; Shahla Bahraini; Zahra Keshavarzi; Ali Firoozabadi; Ali Alavi Shoshtari
Journal:  Iran J Psychiatry       Date:  2017-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.